Blockade of VEGF-A by bevacizumab decreases the microvessel structure density in tumors, reduces tumor volumes (Zhao et al., 2012), and reprograms the tumor immune microenvironment (Tamura et al., 2019), thus providing a rationale for combination strategies. Here, VEGFA is linked to neoplasm.